Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
2.700
-0.080 (-2.88%)
Jun 10, 2026, 4:00 PM EDT - Market closed
Tvardi Therapeutics Employees
Tvardi Therapeutics had 12 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,286,583
Market Cap
25.33M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | 0 | - |
| Dec 31, 2024 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Longeveron | 38 |
| Palatin Technologies | 29 |
| NeuroSense Therapeutics | 17 |
| Quantum BioPharma | 17 |
| Serina Therapeutics | 16 |
| BriaCell Therapeutics | 16 |
| Neuphoria Therapeutics | 8 |
TVRD News
- 3 days ago - Tvardi Therapeutics initiated with a Buy at H.C. Wainwright - TheFly
- 20 days ago - Tvardi Therapeutics to Participate in Upcoming Investor Events - GlobeNewsWire
- 4 weeks ago - Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c) - TheFly
- 4 weeks ago - Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Tvardi Therapeutics files $200M mixed securities shelf - TheFly
- 7 weeks ago - Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays - TheFly
- 2 months ago - Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium - GlobeNewsWire
- 2 months ago - Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler - TheFly